The group's principal activity is the research and development of therapies that would use stem and progenitor cells to treat and possibly cure, human diseases and injuries. These therapies are developed to treat and cure neurodegenerative diseases, demyelinating disorders, spinal cord injuries, stroke, hepatitis, chronic liver failure, and diabetes. It derives revenues mainly from collaborative agreements and grants received.
